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Delayed drug hypersensitivity reactions are clinically diverse reactions that vary from
isolated benign skin conditions that remit quickly with no or symptomatic treatment,
drug discontinuation or even continued drug treatment, to the other extreme of severe
cutaneous adverse reactions (SCARs) that are associated with presumed life-longmemory
T-cell responses, significant acute and long-term morbidity and mortality. Diagnostic “in
clinic” approaches to delayed hypersensitivity reactions have included patch testing (PT),
delayed intradermal testing (IDT) and drug challenges for milder reactions. Patch and IDT
are, in general, performed no sooner than 4–6 weeks after resolution of the acute reaction
at the maximum non-irritating concentrations. Functional in vitro and ex vivo assays have
largely remained the province of research laboratories and include lymphocyte
transformation test (LTT) and cytokine release enzyme linked ImmunoSpot (ELISpot)
assay, an emerging diagnostic tool which uses cytokine release, typically IFN-γ, after
the patient’s peripheral bloodmononuclear cells are stimulated with the suspected drug(s).
Genetic markers such as human leukocyte antigen have shown recent promise for both
pre-prescription screening as well as pre-emptive and diagnostic testing strategies.
Keywords: delayed hypersensitivity reaction, drug allergy, severe cutaneous adverse reactions, T cells, skin testing,
lymphocyte transformation test (LTT), enzyme linked ImmunoSpot (ELISpot), HLA
INTRODUCTION
In this review, we will address the immune mechanisms of delayed hypersensitivity and how they have
formed the premise for diagnostic methods used in the clinic and research laboratory such as intradermal
skin testing (IDT), patch testing (PT) and new and investigational laboratory-based methods such as the
lymphocyte transformation test (LTT) and the enzyme linked ImmunoSpot (ELISpot) assay. In addition,
the role of genetic markers such as human leukocyte antigen (HLA) in screening, early diagnosis and
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DELAYED HYPERSENSITIVY REACTIONS
Delayed drug hypersensitivities are predominantly the result of
T-cell mediated reactions of varying severity and clinical
diagnosis such as maculopapular exanthema (MPE), fixed drug
eruption (FDE), symmetrical drug-related intertriginous and
flexural exanthema (SDRIFE), single organ disease (e.g., drug
induced liver injury (DILI) and kidney diseases), acute
generalized exanthematous pustulosis (AGEP), drug reaction
with eosinophilia and systemic symptoms (DRESS), Stevens-
Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
MPE or morbilliform drug eruption is the most common of
the self-limiting reactions to drugs characterized by erythematous
macules and papules that can become generalized and confluent
and are associated with pruritis and/or mild eosinophilia (Peter
et al., 2017). FDE is characterized by red dark lesions localized in
the same area after drug re-exposure that might be accompanied
by a burning or itchy sensation (Rive et al., 2013). SDRIFE is
characterized by a well-demarcated macular eruption involving
the flexural or intertriginous folds, inguinal and peri-genital as
well as gluteal and peri-anal areas (Wolf and Tuzun, 2015). DILI
generally manifests as an isolated hepatitis with multiple
metabolic, immune and genetic factors considered causal (Rive
et al., 2013). However, some patients can present with features of
hypersensitivity such as fever and skin eruption as well as pruritus
with secondary excoriations. AGEP is a non-follicular sterile
pustular eruption over widespread erythema, with a
predilection for the flexural folds, and accompanied by fever
and/or biological abnormalities (Peter et al., 2017). A validation
score from the EuroSCAR group criteria can be used to confirm
the clinical diagnostic for AGEP cases (Sidoroff et al., 2001). The
main clinical features of DRESS or drug-induced hypersensitivity
syndrome (DIHS) are erythematous urticaria-like plaques or
violaceous skin eruption that can progress to exfoliative
dermatitis, facial and extremity edema, lymphadenopathy,
fever, biological abnormalities and internal organ involvement.
The European Registry of Severe Cutaneous Adverse Reactions
(RegiSCAR) score is calculated using clinical and laboratory data
to determine the likelihood of disease (definite, probable, possible
or no case) (Kardaun et al., 2007). Another multisystem disease
related to drug exposure is the abacavir hypersensitivity
syndrome (AB HS) that is characterized by constitutional
symptoms including fever, gastrointestinal manifestations and
skin eruption (Clay, 2002; Phillips et al., 2002).
SJS and TEN are characterized by skin detachment and full-
thickness epidermal necrosis of various severities depending of
the body surface area (BSA) affected (1–10% for SJS, 10–30% for
SJS/TEN overlap and >30% for TEN) as well as blistering of
mucous membranes accompanied by other serious systemic
manifestations (Peter et al., 2017). As the mortality can reach
30–50% (Rive et al., 2013), a validated clinical score of toxic
epidermal necrosis (SCORTEN), can be calculated at admission
to predict mortality (Bastuji-Garin et al., 2000). Drug causality
can be assessed with the algorithm of drug causality for epidermal
necrolysis (ALDEN) score, an algorithm that helps identify the
most likely causal drug(s) based on criteria such as type of drug,
timing and possible alternative causes (Shear and Dodiuk-Gad,
2019). The time from the drug exposure to the development of
symptoms can vary from 4 to 28 days and, in one third of cases,
no causal agent is identified (Duong et al., 2017). The spectrum of
T-cell mediated phenotypic scoring tools are outlined in Table 1.
Mechanisms of Immune Response in
Delayed Hypersensitivities
With a better understanding of the pharmacogenomic and
pathogenesis of drug reactions, newer classifications of adverse
drug reactions that enhance our understanding of the drug
hypersensitivity framework have been suggested. The on-
target/off-target model categorizes adverse drug reactions by
describing the interactions between drugs and their known
targets for the desired pharmacological effect as well as the
known or unknown mechanism for an off-target effect (White
et al., 2015; Phillips, 2016). On-target reactions are generally non-
immunologically mediated, dose-dependent and related to the
primary pharmacologic mechanism of action of the drug. Off-
target effects can relate to a number of known toxic, non-
immunological and immunological mechanisms and can be
subclassified in 1) dose dependent interactions with off-target
receptors and pharmacological interactions such as non-IgE
mediated mast cell activation or cellular toxicity and 2) drug
allergy with immunological memory of variable duration such as
delayed T-cell mediated reactions or IgE-mediated reactions
(White et al., 2015). This is illustrated in Figure 1.
A well-established classification of historical relevance is the
Gell and Coombs criteria of T-cell mediated hypersensitivity
where type IVa is marked by T helper 1 (Th1) cells,
macrophages and a secretion of IFN-γ, TNF-α, IL-18; type
IVb by Th1 and other components such as B cells, IgE, IgG4,
mast cells, eosinophils with a marked secretion of IL-4, IL-5 and
IL-13; type IVc characterized by cytotoxic T cells that secrete
granzyme, B perforin and granulysin and type IVd, where Th1/
Th17 cells and neutrophils act through cytokine mediators such
as GM-CSF, IL-8 and CXCL8 (Pichler and Hausmann, 2016). As
the different phenotypes of delayed T-cell mediated reactions
have different effector cells and cytokines, they have been
portrayed under one of these subcategories with SJS/TEN
probably related with CD8+ T-cell infiltrates (type IVc) and
DRESS with a CD4+ dominant T-cell infiltration (type IVb)
(Hari et al., 2001). The clear divergence in predominant
cytokine signature between T-cell subsets provided indication
TABLE 1 | Clinical diagnosis and described scoring algorithms.
Clinical diagnosis AGEP DRESS SJS/TEN
Disease likelihood AGEP validation score RegiSCAR score None
Drug causality Naranjo score Naranjo score ALDEN score
Naranjo score
Mortality None None SCORTEN
AGEP, acute generalized exanthematous pustulosis; DRESS, drug reaction with
eosinophilia and systemic symptoms; SJS/TEN, SJS/TEN, Stevens-Johnson syndrome/
toxic epidermal necrolysis. ALDEN, algorithm of drug causality for epidermal necrolysis;
Naranjo score: The Adverse Drug Reaction (ADR) Probability Scale; RegiSCAR,
european registry of severe cutaneous adverse reactions; SCORTEN, score of toxic
epidermal necrosis.
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for their detection to drive response categorization in each patient
(see ELISpot section below).
This classification only partially accounts for underlying
immunological mechanisms and does not explain the specific
mechanism by which drugs may activate T cells. Three non-
mutually exclusive hypotheses have been described to clarify drug
triggered T-cell activation: 1) the p-i concept, 2) the hapten/pro-
hapten model and 3) the altered peptide repertoire model
(Figure 1). The pharmacological-interaction (p-i) model
suggests that the offending drug can rapidly stimulate T cells
by directly binding non-covalently to either T-cell receptor (TCR)
or HLA (without antigen processing) (Pichler and Hausmann,
2016). This concept was proposed after observation that protein-
unreactive drugs can stimulate T cells (Pichler andWatkins, 2014;
White et al., 2015). In the hapten/pro-hapten model, novel
antigens are generated from endogenous proteins that
covalently bind the culprit drug or its metabolites, forming a
neoantigen that then triggers T-cell response (Pichler and
Hausmann, 2016). Haptens are small reactive molecule that
become antigenic by covalent binding to high-molecular-
weight autologous extracellular or cytoplasmic proteins. The
resultant “haptenated” product undergoes presentation by
APC on HLA molecules with subsequent activation of T cells.
In this setting, re-exposure will generate rapid memory T-cell
proliferation and inflammatory response. A classic example is the
binding of penicillin metabolites to serum albumin (Padovan
et al., 1996). Finally, in the altered peptide repertoire model, the
causal drug occupies a position in the HLA peptide binding
groove altering the binding cleft and the specificity of self-
peptides able to bind to the HLA molecule (Illing et al., 2012).
This model has only been established for abacavir
hypersensitivity with the crystal structure of abacavir bound to
peptide and HLA-B*57:01 having been described. It has hence
been elucidated through this structure, peptide binding studies
FIGURE 1 | T-cell mediated delayed hypersensitivity mechanistic hypotheses. Three non-mutually exclusive hypotheses have been described to clarify drug
triggered T-cell activation: (A) The hapten/prohapten model describes how an antigen (drug) that covalently binds to a self-peptide is intracellularly processed and then
presented by MHC to T cells. (B) The p-i concept (pharmacological interaction with immune receptor) is based upon non-covalent binding of antigens to HLA or TCR
without immune processing. (C) The altered repertoire model indicates that drugs can occupy positions in the peptide binding groove of the MHC, altering the
binding cleft and the specificity of MHC binding. HLA, human leukocyte antigens; MHC, major histocompatibility complex; TCR, T-cell receptor.
Frontiers in Pharmacology | www.frontiersin.org January 2021 | Volume 11 | Article 5735733
Copaescu et al. Diagnostic Methods in Delayed Drug Hypersensitivity
and peptide elution studies that abacavir binds non-covalently
within the F pocket of the peptide-binding cleft of HLA-B*57:01
and alters the normal C9 peptide specificity from aromatic
aliphatic amino acids, such as phenylalanine, to linear
aliphatic amino acids, such as leucine, isoleucine and valine
(Illing et al., 2012; Ostrov et al., 2012).
DIAGNOSTIC METHODS
Drug Challenge
In the context of drug allergy, drug challenge in a patient with
suspected drug-induced hypersensitivity remains the gold
standard for determining tolerance (Aberer et al., 2003). For
immediate reactions, such as IgE mediated reactions, a negative
drug challenge has a 100% negative predictive value. However, in
the case of a severe delayed reaction, re-challenge with a single
dose of a drug may not reproduce the reaction and, hence, it has a
lower sensitivity than a prolonged challenge (3–5 days),
particularly with a remote reaction (Bousquet et al., 2008;
Hjortlund et al., 2012). In particular settings such as childhood
non-specific delayed mild exanthem associated with antibiotics in
the context of a possible viral infection, there is increase evidence
that direct oral challenge is a safe diagnostic tool (Mill et al., 2016;
Trubiano et al., 2017a).
In addition, with high severity reactions, drug challenge carries
an inherent risk and the benefit of re-challenge has to be carefully
weighed against the risk of a serious reaction. In cases of severe
cutaneous adverse reactions or severe organ involvement,
challenges are contraindicated because of the risk of a life-
threatening clinical reaction (Rive et al., 2013; Trubiano and
Phillips, 2013). In this context, investigational tools have been
developed to aid drug evaluation. In vivo testing such as PT and
delayed IDT and ex vivo assays such as the LTT and ELISpot have
been described for various drugs and phenotypes but lack
international validation. Combining in vivo and ex vivo
methods in delayed hypersensitivity reactions can increase the
diagnostic yield, although this has been shown in only small
cohort studies (Trubiano et al., 2018).
Skin Testing
In vivo testing (PT and delayed IDT) is usually performed to the
implicated drug(s) at least 4–6 weeks after delayed
hypersensitivity resolution at the recommended non-irritating
concentrations (Phillips et al., 2019).
Patch Testing
The main types of reactions where PT is used with high
specificity are MPE, AGEP, DRESS, SJS/TEN and FDE
(Ozkaya-Bayazit et al., 1999; Barbaud et al., 2001; Barbaud
et al., 2013). The sensitivity of this investigational tool varies
depending on the clinical setting, the causal drug, the drug
concentrations used and the phenotype with typical figures for
AGEP at 58–64% (Wolkenstein et al., 1996; Barbaud et al.,
2013), DRESS between 32 and 80% (Barbaud et al., 2013;
Barbaud, 2014) and SJS/TEN, 9–24% (Wolkenstein et al.,
1996; Barbaud et al., 2013). Drugs like antiepileptics,
contrast media, beta-lactams, tetrazepam and pristinamycin
increase the sensitivity of PT (Johansen et al., 2015), while
allopurinol or its active metabolite, oxypurinol, appear to
never provide clinical utility.
The testing should be performed at least one month after the
resolution of the reaction or after discontinuation of oral steroids,
as immunosuppressants can decrease T-cell mediated immunity,
and preferably during the first year after the reaction. The
European Network on drug allergy (ENDA) and the European
Academy of Allergy and Clinical Immunology (EAACI)
recommend timing between 3 weeks and 3 months and
describe drug concentrations between 5 and 30% with most
antimicrobials diluted at 20% (Brockow et al., 2002) or 30%
(Barbaud et al., 2001) in petrolatum vehicle and the retained
vehicle alone as negative control (Barbaud et al., 2001; Brockow
et al., 2013). For DRESS, patch testing may be further delayed
because of the concomitant dosing of topical or systemic steroids
or other immunosuppressants and to avoid confusion with
DRESS relapse. Available literature suggests that the yield
from patch testing for SJS/TEN is in general low but
dependent on the drug and class of drugs. Sensitivities will
vary from 0% for allopurinol to >50% for aromatic
antiepileptic drugs such as carbamazepine (Konvinse et al., 2016).
The two forms of PT described are the extemporaneous,
involving the local preparation of the PT by the pharmacy or
the drug allergy staff with commercially available drugs and
petrolatum or water, and the conventional PT implying use of
a limited number of ready-to-use commercialized PT products at
10% concentration in petrolatum (Chemotechnique, Sweden). In
a retrospective study, 21/75 (23.3%) patients with MPE, FDE,
AGEP, DRESS, SJS/TEN tested simultaneously with both
methods had positive results, indicating that both methods are
as valuable and reliable (Assier et al., 2017). PT is usually applied
in the upper back regions for practical reasons with the exception
of FDE in which the PT is applied on the region of the previous
reaction. The International Contact Dermatitis Research Group
have published an interpretation score for the patch test reactions
(Table 2) (Barbaud et al., 2001).
In a large multi-center patch testing cohort, only one patient
(1/134) presented a relapse of his skin condition (AGEP)
following patch testing (Barbaud et al., 2013) indicating that
this diagnostic method carries low morbidity. In a retrospective
review including 826 patients, PT showed promising results for
drug challenge outcomes with 82.3% (14/17) with positive PT
having a positive challenge and 90.4% (207/229) patients with
TABLE 2 | Score—Interpretation of patch testing reactions.
Score Interpretation
− Negative reaction
? or +/− Doubtful reaction, faint erythema
+ Weak reaction, erythema, slight infiltration
++ Strong reaction, erythema, infiltration, papules or vesicles (bullae)
Reaction may extend beyond the margins of the patch
+++ Extreme, bullous, ulcerative
IR Irritant reaction: Follicular, pustular, bullous or necrotic
NT Not tested
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negative PT presenting no reaction to challenge (Lammintausta
and Kortekangas-Savolainen, 2005).
PT is a quick and safe investigational method clinically
relevant when testing is conclusive, a negative PT not
excluding the possibility that the drug is causal. There is need
to re-challenge negative testing in less severe clinical phenotypes.
This method should be homogenized, as to resolve current
inconsistencies, by comparing the outcomes in large
multicenter studies, determining concentration thresholds and
avoiding false negative and false positive results.
Intradermal Testing
Intradermal testing is done on the volar aspect of the forearm
with 0.02–0.05 ml of antibiotic reagent or normal 0.9% serum
saline (negative control) (Empedrad et al., 2003a; Brockow et al.,
2013). The use of IDT is limited to drugs available in liquid sterile
formulations. The positive control normally used is a skin prick
test with histamine 10 mg/ml (Heinzerling et al., 2013). In terms
of drug concentrations, expert consensus advises the use of the
highest non-irritating concentration described for immediate
reactions (Phillips et al., 2019). However, recent work for
drugs with non-IgE mast cell activation determined that
higher concentrations that might initially be irritating are
needed for improved sensitivity (i.e., ciprofloxacin,
vancomycin) (Brockow et al., 2002; Brockow et al., 2013;
Konvinse et al., 2016). An IDT result is considered positive
when the dermal induration and erythema at the injection site
exceeded 5 mm from baseline (Empedrad et al., 2003b; Brockow
et al., 2013). Delayed reading is performed at 24, 48 h and up to
1 week (Empedrad et al., 2003b; Brockow et al., 2013). IDT with
delayed reading has been described in reactions such as MPE,
AGEP and DRESS with potential risk in SJS/TEN and unknown
utility in FDE (Table 3). This investigational tool was previously
considered potentially harmful in SCAR phenotypes but actually
few reports describe severe systemic reactions following IDT
(Makris et al., 2010; Sala Cunill et al., 2011; Syrigou et al.,
2016; Watts, 2017). For SJS/TEN, based on the current
available literature, the benefit of IDT does not outweigh the
risk. For DRESS, it is recommended that testing generally be
deferred 6 months following the acute reaction.
In terms of cross-reactivity between beta-lactams in the
context of delayed hypersensitivities, 18.7–31.2% of the
patients tested presented a reaction to amino-penicillins and
amino-cephalosporins (Dash, 1975) predicted by the presence
of shared R1 and R2 side chains (Buonomo et al., 2014; Romano
et al., 2016). Also, in patients with a delayed penicillin type
reaction, delayed IDT to beta-lactams has allowed to confirm
tolerance to cephalosporins (Picard et al., 2019; Trubiano et al.,
2020), carbapenems (Gaeta et al., 2015; Picard et al., 2019) and
monobactams (Buonomo et al., 2011). Other classes of interest
are currently being studies with no evidence of cross-reactivity
such as glycopeptides (Empedrad et al., 2003a), antibiotic and
non-antibiotic sulfonamides (Empedrad et al., 2003a;
Lammintausta and Kortekangas-Savolainen, 2005), drugs in
the rifampin class (Lammintausta and Kortekangas-Savolainen,
2005) and aromatic and non-aromatic anticonvulsants
(Heinzerling et al., 2013).
In the setting of a severe delayed reaction, PT is related to
lower adverse reactions but IDT has been described as more
sensitive in non-SJS/TEN reactions (Osawa et al., 1990; Barbaud
et al., 2001; Cabanas et al., 2014) while some recommendations
only suggest proceeding to IDT after negative PT (Brockow et al.,
2002). In a cohort study of 21 patients with delayed reactions to
penicillin and 30 controls with no allergic history, no false
positives were reported and 20/21 were positive for IDT
compared to 18/21 for patch testing (Torres et al., 2004).
Widespread implementation of IDT for delayed
hypersensitivities still carries some barriers such as the lack of
available sterile preparation for all drugs, generally low negative
predictive value (NPV) and limited data in some reactions.
Ex Vivo Diagnostic Tools
In vitro/ex vivo diagnostics, such as the LTT and the ELISpot
assay, while having the advantage of carrying no risk of drug re-
exposure for the patient, are not available for routine diagnostic
use in most centers. A practical management approach for
delayed T-cell mediated hypersensitivity reactions is illustrated
in Figure 2.
Lymphocyte Transformation Test
LTT has been extensively studied as a diagnostic method for
delayed hypersensitivity reactions. Lymphocytes are isolated
from the patient’s peripheral blood mononuclear cells (PBMC)
and cultured with pharmacological concentrations of the
TABLE 3 | Role of diagnostic/screening tests in delayed drug hypersensitivity reactions.
In vivo Ex vivo
Clinical diagnosis Patch testing Delayed IDT Oral challenge LTT ELISpot HLA
MPE Yes ) Yes ) Yes No No No
AGEP Yes Yes No Equivocal Equivocal No
DRESS/DIHS Yes Yes No Yes Yes Yes ψ
SJS/TEN Yes No No Yes Yes Yes ψ
FDE Yes ω No Equivocal No No No
SDRIFE Yes ω Equivocal Equivocal No No No
AGEP, acute generalized exanthematous pustulosis; DIHS, Drug-induced Hypersensitivity syndrome; DRESS, Drug reaction with eosinophilia and systemic symptoms; ELISpot, enzyme-
linked immunospot; FDE, fixed drug eruption; HLA, human leukocyte antigen; LTT, Lymphocyte transformation test; SDRIFE, symmetrical drug-related intertriginous and flexural
exanthema, SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis.)As the sensitivity for PT and IDT is poor, drug challenge of the implicated drug can be considered. PT/IDT
may give information on cross-reactivity ω PT should be applied on the region of the previous reaction ψ HLA screening is not routinely used globally in clinical practice. Please refer to
Table 4 for details.
Frontiers in Pharmacology | www.frontiersin.org January 2021 | Volume 11 | Article 5735735
Copaescu et al. Diagnostic Methods in Delayed Drug Hypersensitivity
suspected drugs for 5–7 days. LTT responses are measured by
the stimulation index (SI, average proliferation of drug-
exposed cultures/average proliferation of negative control
cultures), with typically an SI > 2+ confirming response,
which is calculated based on the radioactive thymidine
(H-thymidine) uptake, a marker directly proportional to
the degree of T-cell proliferation in response to a drug
antigen (Pichler and Tilch, 2004). This enhanced response
is interpreted as a T-cell sensitization and has produced
positive responses in different clinical settings and with
various implicated drugs (Rive et al., 2013). However, one
might keep in mind that lymphocyte stimulation can occur
not only by immunological mechanisms but also
pharmacological ones and some drugs may cause false
positive results as was observed in some patients that
presented positive responses to drugs they had tolerated
(Pichler and Tilch, 2004).
The reported sensitivity of LTT in delayed hypersensitivity
reactions ranges from 27% (Porebski et al., 2013) to 74%
(Nyfeler and Pichler, 1997) and specificity was quoted as
85% (Nyfeler and Pichler, 1997; Rozieres et al., 2009) to
100% (Porebski et al., 2013; Porebski et al., 2015). Putting
aside the demanding and time-consuming laboratory
manipulations and the use of radioactivity and specialist
equipment, the LTT can be an interesting support in drug
hypersensitivity diagnosis but is still only used as a research
tool (Pichler and Tilch, 2004; Nagao-Dias et al., 2009). The
largest study describes LTT in 923 patients with suspected
hypersensitivity among which only 100 patients had a
confirmed drug hypersensitivity reaction and 58/78
penicillin allergy labeled patients presented a positive LTT
(Picard et al., 2019). In the last 10 years, aside from case reports
or small cases series (Kim et al., 2013; Cabanas et al., 2014; Dias
de Castro et al., 2015; Tomida et al., 2016), very few studies
have focused solely on the LTT method for diagnosis.
Enzyme Linked ImmunoSpot
The ELISpot technique quantifies the secretion and activation of
drug-specific cells by determining the number of spot-forming
units (SFU) or spot-forming cells (SFC) that release cytokine
markers or cytolytic molecules after the patient’s PBMC is
activated with the suspected drug(s) (Figure 3). The patient’s
cells are added to a 96-well plate coated with specific anti-
cytokine antibody depending on the expected measured T-cell
response. In drug-induced delayed hypersensitivity, interferon
gamma (IFN-γ), a key Th1-type cytokine, is released from
activated T cells, while granzyme B (GrB), a serine protease, is
released from cytoplasmic granules within cytotoxic T cells and
natural killer cells. Anti-CD3 antibodies, a mix of viral peptides
CEF (cytomegalovirus (CMV), Epstein-Bar Virus (EBV) and
influenza (FLU)) and tetanus toxoid can be used as positive
controls as they stimulate INF-γ release from CD8+ T cells. The
background immunological activation can be assessed with
negative controls (cells and media). Cytokine secretion is
captured by the anti-cytokine antibodies in the next 24–48 h
with detection antibody and enzyme substrate being added just
before reading the plate. The SFU representing cells that secrete
cytokines are then identified and counted. As the incubation time
is shorter than for LTT and T-cell activation occurs after 48–72 h,
this could be a promising technique. However, one must consider
the often-diverse response between replicates and the researcher
intensive laboratory manipulations.
In a recent study, the sensitivity of this technique in patients
with SCAR was 52%, 10/19 patients presenting a positive IFN-γ
ELISpot (>50 SFU/106), with a specificity of 100% (Trubiano
et al., 2018). The GrB ELISpot has a lower sensitivity (33%; 5/15
positive patients (>20 SFU/well) (Porebski et al., 2013) up to 55%;
13/23 positive patients (>0 SFU) (Porebski et al., 2015)) and
similar specificity. However, when compared to LTT, ELISpot
seems to have a better sensitivity (Rozieres et al., 2009).
Depending on the positive ELISpot assay definition, the
FIGURE 2 | Diagnostic approach to delayed hypersensitivity reactions. 1) Clinical history and identification of possible causal drugs; 2) Patch testing; 3) Intradermal
testing reading after 24–48 h; 4) Ex-vivo testing (if available): ELISpot, LTT, HLA allele testing; 5) Single or prolonged drug challenge if conclusive results. ELISpot, enzyme
linked ImmunoSpot; HLA, human leukocyte antigens; LTT, lymphocyte transformation test.
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number of confirmed cases varies with several studies considering
the unique presence of SFU as sufficient for a positive test (Khalil
et al., 2008; Porebski et al., 2015; Castagna et al., 2018). A recent
study from our group reported 5/12 positive ELISpot among SCAR
patients with a 50 SFU/106 cut-off (Trubiano et al., 2020). However,
in a cohort of 22 patients with amoxicillinMPE, the sensitivity of the
IFN-γ ELISpot was 91% (15/22) when the cut-off used was more
than 30 SFU/106 (Rozieres et al., 2009). Using this same reference
value, the sensitivity was 87.5% (7/8) in a study involving eight
patients with hypersensitivity to piperacillin (El-Ghaiesh et al., 2012).
Finally, some authors determine a positive value based solely on the
SFU detection level in controls (Suthumchai et al., 2018). Because of
the current controversy in the literature, our definition of a positive
response is equal or greater than 50 spot-forming unit (SFU)/million
cells after background (unstimulated control) (Keane et al., 2012).
As discussed, LTT and ELISpot do not have a good sensitivity
especially when the blood is collected during the acute reaction.
One hypothesis is that the reactive cells are not found in the
circulation or that overstimulated lymphocytes could be
exhausted. Thus, a cytokine or cytolytic marker panel could
help delineate the implicated mediators. While alternative cell
viability and proliferative assays have been developed in recent
years including several variants of the MTT and
carboxyfluorescein succinimidyl ester (CFSE) staining assays,
these have not widely been applied for diagnostic investigation
due to issues surrounding potential drug-inhibition of
FIGURE 3 | Detection of cytokine secretion using ELISpot. Cytokine-specific coating antibody is added and incubated overnight at 4°C. The plate is washed and
PBMCs and drug(s) are added and incubated for 18–20 h at 37°C. The following day, the plate is washed again and biotin-conjugated detection antibody is added and
incubated for 2 h at room temperature. After another wash, streptavidin-bound enzyme is added and incubated for 1 h at room temperature. After the last wash,
substrate is added (BCIP-NBT or TMB). Spot development is monitored for ∼15 min (in dark). The plate is washed and left to dry overnight for a final reading on the
fourth day. BCIP-NBT, 5-bromo-4-chloro-3-indolyl phosphate (BCIP)/nitro blue tetrazolium (NBT); ELISpot, enzyme linked ImmunoSpot; PBMC, peripheral blood
mononuclear cells; TMB, tetramethyl benzidine.
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metabolism-dependant colorimetric conversion and flow
cytometer access, and difficulties in staining, respectively.
Biomarkers in Adverse Drug Reactions
As the most severe reactions but also those with the most varied
clinical presentations are SJS/TEN and DRESS/DiHS, research
efforts have been concentrated to develop new biomarkers with a
particular interest in cytokines and chemokines released from
activated T cells.
Studies on cytokine measurements after clinical drug
challenge in patients with the generalized form of FDE
clinically and histologically mimicking SJS/TEN have
reported an initial increase in serum TNF-α and IL-8
followed by elevation in IFN-γ, IL-6 and IL-10 levels
(Kauppinen, 1991; Correia et al., 2002; Shiohara et al.,
2015). Similarly, dosage of levels for multiple cytokines/
chemokines in order to identify essential markers has also
been attempted with studies identifying a significant increase
in IL-6 and interferon gamma-produced protein 10 (IP-10) in
SJS/TEN and DRESS as well as IL-16 in FDE, SJS and DRESS
but not TEN (Shiohara et al., 2015). These authors go to
recommend the use of IL-6 and IL-10 as diagnostic and
predictive tools in monitoring adverse drug reactions
(Shiohara et al., 2015). On a cautionary note, these markers
may be elevated in other conditions such as acute infection and
sepsis.
Further, serum soluble Fas-ligand (sFasL) levels (Posadas
et al., 2002; Abe et al., 2003; Murata et al., 2008), granulysin
(Chung et al., 2008; Porebski et al., 2013; Cho et al., 2014;
Chung et al., 2015; Weinborn et al., 2016), IL-15 (Su et al.,
2017), CD137 (Trubiano et al., 2017b) and the proapoptotic
factor galectin-7 (Hama et al., 2019) have been described in the
pathological processes of SJS/TEN with sFasL and galectin-7
being considered as biomarkers able to predict TEN
progression but not SJS (Shiohara et al., 2015; Hama et al.,
2019) and granulysin serum levels correlating with disease
severity and mortality (Chung et al., 2008; Chung et al., 2015).
In DRESS/DiHS, several markers were reported as indicators
of disease progression and activity such as the serum thymus
and activation-regulated chemokine (TARC) (Ogawa et al.,
2013; Komatsu-Fujii et al., 2017; Komatsu-Fujii et al., 2018)
and granulysin (Saito et al., 2012). Other markers such IL-2,
IL-4, IL-5, IL-13, IFN-γ and granzyme-B have been described
in T-cell drug hypersensitivity (Lochmatter et al., 2009;
Zawodniak et al., 2010; Polak et al., 2013). Measurement of
these markers was reported using the ELISpot, intracellular
cytokine staining, ELISA, rapid immunochromatographic tests
(Su et al., 2016), plex bead-based immunoassay kits
(Lochmatter et al., 2009) and flow cytometry (Porebski
et al., 2013). Controversial markers are also important to
underline such as IL-17 with some studies reporting a
negative correlation with adverse drug reactions (Shiohara
et al., 2015) while others described an increase of this
cytokine in SJS/TEN (Teraki et al., 2013). Similarly,
procalcitonin has been described as a marker for bacterial
infection that could benefit the differential diagnostic that
includes delayed hypersensitivity (Yoon et al., 2013).
In the early stages of severe delayed hypersensitivity
disease, laboratory tests that can be used in clinical routine
are needed to predict disease progression and to monitor
treatment responses.
High-Resolution Human Leukocyte Antigen
Class I and II Typing
The association between particular class I HLA alleles and specific
phenotypes such as allopurinol SJS/TEN and DRESS (HLA-B*58:
01), carbamazepine SJS/TEN (HLA-B*15:02) and abacavir
hypersensitivity reaction and flucloxacillin drug-induced liver
injury (HLA*57:01) has allowed a better understanding of the
immunopathogenesis of severe T-cell mediated delayed
hypersensitivity reactions and the implementation of
guidelines and screening programs in the case of HLA-B*57:01
and abacavir and HLA-B*15:02 and carbamazepine in Southeast
Asian populations in particular (Table 4).
DNA from patients with drug reactions can be obtained by a
routine blood draw and extracted from whole blood or
extracted from saliva collected into, for instance, a gene
collection kit. DNA can then be used to perform high
resolution HLA class I and II typing with next generation
sequencing methods. To facilitate HLA testing with rapid
turnaround times, cost-effective single allele assays have
been developed for many class I HLA alleles such as HLA-
B*57:01, HLA-B*15:02 and HLA-A*32:01 with parallel allele
specific quality assurance programs which was crucial for the
widespread global implementation of HLA-B*57:01 screening
programs. HLA genes encode cell-surface protein receptors
that present antigenic peptides to T cells. Class I MHC
molecules (HLA-A, B and C) are expressed on most
nucleated cells and are responsible for presenting peptides
to CD8+ cytotoxic T lymphocytes. Class II MHC molecules
(HLA-DP, DQ and DR) are expressed only on antigen
presenting cells (B cells, macrophages and dendritic cells)
and stimulate CD4+ helper T lymphocytes. The association
between HLA and disease confers explanations on disease
susceptibility with HLA polymorphisms playing a crucial
role in T-cell repertoire and auto-reactive T cells, immune
system presentation, recognition and antigen processing and
the adaptability of the immune system (Shiina et al., 2004).
Also, HLA allele have a different prevalence in different ethnic
groups and this might explain the increased drug reactions in
specific populations (Rive et al., 2013). The global
epidemiology of severe cutaneous adverse drug reactions is
illustrated in Figure 4.
Currently, screening for HLA-B*57:01 prior to abacavir
prescription is the standard of care in HIV clinical practice
across the developed world. When screening occurs and is
acted upon, it eliminates abacavir hypersensitivity (Mallal
et al., 2008). Another example is screening for HLA-B*15:02
before initiating treatment with carbamazepine to avert SJS/
TEN in some Southeastern Asian countries with increased
prevalence. The xanthine oxidase inhibitor, allopurinol, was
also associated with SJS/TEN and DRESS and HLA-B*58:
01genotyping in Han Chinese showed 100% NPV and 3%
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PPV (Hung et al., 2005), however it has incomplete negative
predictive value in European and African populations where
50–60% of patients with allopurinol DRESS/SJS/TEN do not
carry HLA-B*58:01 (Lonjou et al., 2006).
Many of the described HLA alleles associations have a close to
100% negative predicting value, however this is highly dependent on
the prevalence of the HLA allele in the population and the risk
allele(s) in different populations. For instance, for allopurinol SJS/
TEN and DRESS and HLA-B*58:01, it has almost a 100% NPV in
Southeast Asian population however explains only 50–60% of
allopurinol DRESS/SJS/TEN in European and African
populations. The number needed to test to prevent one case of
disease is thus population specific. However, as the prevalence of
these diseases in the general population is reduced, more targeted
populations could benefit from screening.
Recommendations
• Patch testing and intradermal testing can be used in the
clinical setting for specific clinical diagnosis of
T-mediated delayed hypersensitivity reactions while
appreciating that preparations and drug concentration
should be standardized to optimize their use.
• While skin testing (patch testing and intradermal testing)
has a high drug specificity, both have phenotype and drug
dependent sensitivity and incomplete NPV and, in the
setting of severe delayed drug reaction, clinical history is
the main determinant of drug safety that guides the
decision for drug challenge or future drug use.
• Different non-irritating drug concentrations have been
described for intradermal and patch testing. However,
global consensus is lacking and clinicians are encouraged
to follow the most recent drug allergy guidelines.
• Intradermal testing can be safety performed for non-SJS/
TEN delayed reactions. Patch testing is the initial in vivo
investigational tool that can be used for severe delayed
reactions such as SJS/TEN.
• Ex vivo tools such as the lymphocyte transformation test
and the enzyme-linked ImmunoSpot assay are currently not
available for routine clinical practice and are used solely
in specialized center. Collaborating with such a center
will not only improve patient care but could benefit
research in this field.
• In the early stages of severe delayed hypersensitivity disease,
laboratory tests that can be used in clinical routine are
needed to predict disease progression and to monitor
treatment responses. There are currently no tests that
should be order on a routine basis.
• Strong HLA associations with delayed T-cell mediated
hypersensitivity reactions have enlightened our
understanding of their immunopathogenesis and, in
combination with availability of cost-effective single HLA
testing, have provided a pathway for pre-prescription
screening strategies. In the future, HLA testing may be
increasingly relevant for pre-emptive testing and diagnosis.
• There is currently no diagnostic tool that offers a 100%NPV
for the delayed hypersensitivity reactions and any decision
to reintroduce a drug in the treatment setting should weigh
the risk benefit ratio.
CONCLUSION
Identifying culprit drugs implicated in delayed T-cell mediated
hypersensitivity with the use of exemplary clinical
TABLE 4 | HLA associations in SCAR and DILI with possible clinical implications.
Reference Reaction
type







DRESS Vancomycin A*32:01 European ancestry (6.8%) Pre-emptive) 99.99 0.51 75
African American (4%)
Southeast Asian (<1.5%)
(Daly et al., (2009)) DILI Flucloxacillin B*57:01 European ancestry (5–8%) None 99.99 0.14 13,819
African American (2.5%)
African/Asia (<1%)
(Mallal et al. (2002)) AB HS Abacavir B*57:01 Caucasian (5–8%) HIV positive patients 100 55 13
(Hung et al. (2005)) SJS/TEN Allopurinol B*58:01 Han Chinese (9–11%) None 100 3 250
DRESS Caucasian (1–6%)
(Zhang et al. (2013)) SJS/TEN Carbamazepine B*15:
02ψ
Han Chinese (10–15%) Routine in southeast Asian countries 100 3 1,000
(Zhang et al. (2013)) DRESS Dapsone B*13:01 Papuans/Australian
aborigines (28%)






AB HS, abacavir hypersensitivity syndrome; DILI, drug-induced liver injury; DRESS, drug reaction with eosinophilia and systemic symptoms; HIV, human immunodeficiency virus; NNT,
numbers needed to test (to prevent one case); NPV, negative predictive value; PPV, positive predictive value; SJS/TEN, SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis.
) HLA-A*32:01 testing could have a role in determining the culprit drug (vancomycin) when multiple drugs are implicated in a delayed hypersensitivity reaction.ψ Other described alleles:
HLA-B*15:21, HLA-B*15:11, and HLA-B*15:18.
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phenotyping, clinical drug causality assessment and adjunctive
in vivo and ex vivo testing including HLA-typing is
increasingly useful to guide safe and optimal future treatment.
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GLOSSARY
ADR: adverse drug reactions
AGEP: acute generalized exanthematous pustulosis
ALDEN: algorithm of drug causality for epidermal necrolysis
CEF: cytomegalovirus (CMV) Epstein-Bar Virus (EBV) and influenza (FLU)
CFSE: carboxyfluorescein succinimidyl ester
DILI: drug induced liver injury
DRESS: drug reaction with eosinophilia and systemic symptoms
ELISpot: enzyme linked ImmunoSpot
FBS: fetal bovine serum
FDE: fixed drug eruption
GrB: granzyme B
HLA: human leukocyte antigens
IFN-γ: Interferon gamma
IP-10: interferon gamma-produced protein 10
LTT: lymphocyte transformation test
MHC: major histocompatibility complex
MPE: maculopapular exanthema
MTT: (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
NPV: negative predictive value
PBMC: peripheral blood mononuclear cells
PPV: positive predictive value
SCAR: severe cutaneous adverse reactions
SCORTEN: SCORe of toxic epidermal necrosis





TARC: thymus and activation-regulated chemokine
TCR: T-cell receptor
TEN: toxic epidermal necrolysis
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